Remove Clinical Development Remove Events Remove Licensing
article thumbnail

Actithera draws new investors to radiopharma drug pitch

BioPharma Drive: Drug Pricing

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Dive Brief Actithera draws new investors to radiopharma drug pitch The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Drugs 156
article thumbnail

Viatris Announces Success in Second Pivotal Phase 3 Trial of MR-141 Targeting Presbyopia

The Pharma Data

This unmet need has driven the development of alternative pharmacological options, including topical eye drops like MR-141, which aim to improve near vision through non-surgical means. Details of the VEGA-3 Phase 3 Trial The VEGA-3 study is part of Viatris’ broader clinical development program to evaluate MR-141 for presbyopia.

Trials 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Intellia Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema

The Pharma Data

The most frequently reported adverse events during follow-up were infusion-related reactions (IRRs), which were predominantly grade 1 (mild) and resolved without further complications. Furthermore, Intellia plans to submit a biologics license application (BLA) in 2026 in support of a potential U.S.

article thumbnail

The future of mental health treatment: Zelquistinel’s role

Drug Target Review

Event-driven pharmacology Donello highlights the growing recognition of synaptic plasticity’s crucial role in the biology of depression. “We call this phenomenon ‘event-driven pharmacology.” This means the PD effects of synapse-targeted drugs can significantly outlast their PK.

article thumbnail

Navigating Regulatory Hurdles in Drug Development

DrugBank

As clinical development progresses, pharmaceutical companies must submit periodic updates to regulatory agencies, reporting on patient safety data, adverse events, and protocol modifications. This application is the foundation for obtaining approval to proceed with Phase I human trials.

article thumbnail

FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche

BioPharma Drive: Drug Pricing

Published June 11, 2025 Ben Fidler Senior Editor post share post print email license The FDA on June 11, 2025 approved Nuvation's Ibtrozi for ROS1-positive non-small cell lung cancer. You can unsubscribe at anytime. © 2025 TechTarget, Inc. or its subsidiaries.

FDA 270
article thumbnail

FDA Grants Priority Review for WINREVAIR Label Update Based on ZENITH Trial

The Pharma Data

Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics License Application (sBLA) and granted it priority review status, seeking to update the U.S. The product was developed under a licensing agreement with Bristol Myers Squibb.

Trials 52